Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - DE
$ 4.11
1.73 %
$ 1.46 B
Market Cap
-8.22
P/E
1. INTRINSIC VALUE
Balance Sheet
Evotec SE
| Current Assets | 903 M |
| Cash & Short-Term Investments | 604 M |
| Receivables | 123 M |
| Other Current Assets | 176 M |
| Non-Current Assets | 1.35 B |
| Long-Term Investments | 142 M |
| PP&E | 807 M |
| Other Non-Current Assets | 401 M |
| Current Liabilities | 465 M |
| Accounts Payable | 134 M |
| Short-Term Debt | 149 M |
| Other Current Liabilities | 181 M |
| Non-Current Liabilities | 715 M |
| Long-Term Debt | 477 M |
| Other Non-Current Liabilities | 237 M |
EFFICIENCY
Earnings Waterfall
Evotec SE
| Revenue | 781 M |
| Cost Of Revenue | 606 M |
| Gross Profit | 175 M |
| Operating Expenses | 223 M |
| Operating Income | -47.5 M |
| Other Expenses | 36.4 M |
| Net Income | -83.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Evotec SE
| Net Income | -83.9 M |
| Depreciation & Amortization | 93 M |
| Capital Expenditures | -216 M |
| Stock-Based Compensation | 9.63 M |
| Change in Working Capital | -9.94 M |
| Others | 14.4 M |
| Free Cash Flow | -180 M |
Wall Street Analysts Price Targets
Evotec SE
Wall Street analysts predict an average 1-year price target for EVO of $10 , with forecasts ranging from
a
low of
$8 to a high of $12 .
EVO Lowest Price Target
Wall Street Target
8 USD
94.65%
EVO Average Price Target
Wall Street Target
10 USD
143.31%
EVO Highest Price Target
Wall Street Target
12 USD
191.97%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.0722 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Evotec SE
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
13 years ago
Oct 18, 2011
|
Bought
1.18 K USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
+ 92
|
12.83 USD |
|
13 years ago
Oct 18, 2011
|
Bought
2.56 K USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
+ 200
|
12.82 USD |
|
13 years ago
Oct 18, 2011
|
Sell 1.17 K
USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
- 92
|
12.72 USD |
|
13 years ago
Oct 18, 2011
|
Bought
1.28 K USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
+ 100
|
12.79 USD |
|
13 years ago
Oct 18, 2011
|
Sell 2.55 K
USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
- 200
|
12.76 USD |
|
13 years ago
Oct 18, 2011
|
Sell 1.28 K
USD
|
BANK OF AMERICA CORP /DE/
10 percent owner
|
- 100
|
12.77 USD |
7. News
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside.
seekingalpha.com
- 3 weeks ago
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.
accesswire.com
- 1 month ago
Evotec Announces Change in Management Board
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS.
accesswire.com
- 1 month ago
Comment on Withdrawn Non-Binding Offer
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.
accesswire.com
- 1 month ago
Halozyme withdraws $2.1 bln buyout offer for Evotec
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
reuters.com
- 1 month ago
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torley, president and chief executive officer of Halozyme , shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees.
prnewswire.com
- 1 month ago
Halozyme CEO: Evotec Is Poised for Growth
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.
youtube.com
- 2 months ago
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO , Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.
prnewswire.com
- 2 months ago
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion).
benzinga.com
- 2 months ago
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
accesswire.com
- 2 months ago
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 77% to Evotec's last three-month volume weighted average price on October 15, 2024.
prnewswire.com
- 2 months ago
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
reuters.com
- 2 months ago
8. Profile
Summary
Evotec SE EVO
COUNTRY
DE
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 1.46 B
Dividend Yield
0.00%
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Contact
Essener Bogen 7, Hamburg, 22419
https://www.evotec.com
IPO
Date
Feb. 5, 2004
Employees
5007
Officers
Dr. Cord Dohrmann Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Ian M. Hunneyball
Senior Vice President of Programme Management & Clinical Operations
Ms. Laetitia Rouxel
Chief Financial Officer & Member of Management Board
Dr. Craig Johnstone Ph.D.
Former Chief Operating Officer & Member of Management Board
Ms. Aurelie Dalbiez
Chief People Officer & Member of Management Board
Gabriele Hansen
Senior Vice President & Head of Global Corporate Communications & Marketing
Dr. Christian Dargel
EVice President Global Head of Legal & Compliance
Dr. David Hallet
Executive Vice President
Dr. Christian Wojczewski
Chief Executive Officer
Mr. Volker Braun
Executive Vice President and Head of Global Investor Relations & ESG